CN108849861A - One kind containing fluorocarbon emulsion type organ preservative fluid - Google Patents
One kind containing fluorocarbon emulsion type organ preservative fluid Download PDFInfo
- Publication number
- CN108849861A CN108849861A CN201811155379.8A CN201811155379A CN108849861A CN 108849861 A CN108849861 A CN 108849861A CN 201811155379 A CN201811155379 A CN 201811155379A CN 108849861 A CN108849861 A CN 108849861A
- Authority
- CN
- China
- Prior art keywords
- preservative fluid
- organ
- fluorocarbon emulsion
- emulsion type
- organ preservative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
Abstract
The invention discloses one kind to contain fluorocarbon emulsion type organ preservative fluid, including Oxygen carrying agent, cell oxygen radical protective agent；It further include emulsifier, surfactant, stabilizer, the thickener for adjusting viscosity, electrolyte solution system and the buffer salt solution system for adjusting pH value.Oxygen carrying content can achieve the 2 times or more that general organ saves liquid, isolated organ cell maintenance metabolism needed nutrient matter is provided simultaneously, organ preservation can be carried out under Mild Hypothermal and low-temperature condition, the preservation effect of in vitro liver and kidney, lung can be improved, and saved quality and be better than HTK liquid and UW liquid.
Description
Technical field
The present invention relates to a kind of organ preservative fluids, and in particular to one kind contains fluorocarbon emulsion type organ preservative fluid, for moving
It plants organ to save, belongs to medical domain.
Background technique
Organ transplant depends on the donor of high quality, this is the successful precondition of transfer operation.Organ Techniques of preserving is
One of big pillar of the three of organ transplant is the foundation stone of organ transplant.Using organ preservative fluid to the donor organ after excision
It carries out lavation and carries out static state low temperature preservation to be the known most common organ preserving type.Currently, common device in clinical practice
It includes UW liquid, HTK liquid, Euro-Collins liquid and Celsior liquid etc. that official, which saves liquid,.These main mechanisms for saving liquid are to pass through
Ion concentration is maintained, osmotic pressure is maintained, oxygen free radical scavenger etc. is added and plays a role.
Wherein, kidney 12 can be reserved for by the University Wisconsin liquid (UW) of Wisconsin university of U.S. invention
Hour, liver 8 hours, the standard for being acknowledged as the preservation of liver pancreas kidney saved liquid, was widely used in international organ transplant circle.But
It cannot provide enough oxygen supporting tissue metabolism, and the organ for limiting the longer time saves, and is difficult to support because of viscosity height
Perfusion preservation is unsuitable for that perfusion equipment is cooperated to save quality using organ is improved.HTK liquid has good buffer solution characteristic,
It can inhibit Tissue acidification, and viscosity is low, be easy to spread, but clinical use is not better than UW in the effect that the organs such as liver kidney save
Liquid.
Either traditional static state low temperature saves or room temperature Perfusion preservation, although the metaboilic level of organ and tissue is
It reduces, various metabolic enzymes vigor declines, but is metabolized and stops there is no complete, even if different research prompts are in 4 DEG C of levels, shifting
The 5%-15% of metaboilic level when plant organ still has normal body temperature.So although reducing temperature can be reduced because blood supply is stopped
Anoxic and nutrient dificiency caused by stagnant, reduce that tissue degeneratiaon and necrosis are horizontal, and however, there remains enough oxygen and nutrients
Supply.
Therefore, it is novel to develop one kind, can efficiently maintain saved organ oxygen and nutrient supply, when extending organ preservation
Between, improving the organ preservative fluid for saving quality has important researching value and clinical meaning.
Summary of the invention
Existing UW saves liquid and has the disadvantages that：
1, hyperkalemia hyponatremia easily causes the damage of vascular endothelial cell；
2, colloid composition hydroxyethyl starch (HES) is affected to hemorheology, and easily causes erythrocyte aggregation；
3, viscosity is high, influences perfusion effect；
4, the costs of material such as gossypose, lactobionic acid are high, greatly increase Organ Transplantation Patients clinic expense.And by Germany
The HTK of Brettschneider invention saves liquid, saves liver effect and UW liquid phase is same, two kinds of organ preservative fluids are to receptor's prognosis
The influence of final result does not have apparent strengths and weaknesses.HTK liquid is low-viscosity, low potassium compared to the advantage of UW liquid, so that HTK liquid fills again
It need not be rinsed before note, its dosage and related complication can be reduced.But HTK liquid still have not can avoid it is low in Microcirculation of Liver
Hepatocellular injury caused by warm anoxia-induced apoptosis, the linear disorder of sinus hepaticus, liver cell separation etc. influence the feelings that transplant organ saves quality
Condition.
The purpose of the present invention is overcoming the shortcomings of existing organ preservative fluid product, for clinic provide it is a kind of efficiently, it is convenient, mention
For longer conserving time limit, the novel organ preservative fluid that organ saves quality is improved, it is specially a kind of to contain fluorocarbon emulsion type organ
Save liquid.
Realizing the object of the invention technical solution is：
One kind containing fluorocarbon emulsion type organ preservative fluid, including Oxygen carrying agent, cell oxygen radical protective agent, further includes emulsification
Agent, surfactant, stabilizer adjust thickener, electrolyte solution system and the buffer salt solution for adjusting pH value of viscosity
System.
It is of the present invention to contain fluorocarbon emulsion type organ preservative fluid, wherein Oxygen carrying agent w/v percentage composition 5-
50% (m/V), oxygen radical protective agent 0.001%-5%, emulsifier 0.001-15%, surfactant 0.001-10%, surely
Determine agent 0.001-5%, thickener 0.001-5%, remaining is water.
Further, of the present invention to contain fluorocarbon emulsion type organ preservative fluid, wherein Oxygen carrying agent w/v percentage
Content 10-20% (m/V), oxygen radical protective agent 0.001%-2%, emulsifier 1-10%, surfactant 0.01-5%, surely
Determine agent 0.01-1%, thickener 0.001-2%, remaining is water.
It is of the present invention containing fluorocarbon emulsion type organ preservative fluid, use fluorocarbons to be prepared into emulsion as Oxygen carrying agent
Type organ preservative fluid, so that the oxygen carrying content of emulsion is more than the 2 times or more of blood plasma oxygen carrying content at normal temperature, in Mild Hypothermal and low temperature shape
Under state, can still take enough oxygen for organ deep.
Further, of the present invention containing fluorocarbon emulsion type organ preservative fluid, the Oxygen carrying agent uses fluorine carbon compound
Object is selected from perfluoro bromide octane, perfluorobromine, perfluorodecalin, perfluamine, perfluoro-methyl Perhexiline, perfluor tributyl
One of amine, perfluorodichlorooctane, perfluorobutyl ethylene are a variety of.It is preferred that perfluoro bromide octane, perfluorobromine.
Further, of the present invention to contain fluorocarbon emulsion type organ preservative fluid, the cell oxygen radical protective agent
Selected from one of N-acetylcystein, Allopurinol, adenosine, glutathione or a variety of.It is preferred that N-acetylcystein.
Further, of the present invention containing fluorocarbon emulsion type organ preservative fluid, the thickener agent is selected from sweet dew
One of alcohol, hydroxy ethyl starch, raffinose, lactobionic acid are a variety of.It is preferred that hydroxy ethyl starch, mannitol.
Further, of the present invention containing fluorocarbon emulsion type organ preservative fluid, emulsifier is selected from soybean lecithin, egg
Yellow lecithin, medium chain triglyceride, phosphatide, cholesterol acid ester, cholesterol, olein, one in Pluronic/Lutrol F 108
Kind is a variety of.It is preferred that egg yolk lecithin, median chain triglyceride oil.
Further, of the present invention containing fluorocarbon emulsion type organ preservative fluid, surfactant is selected from Pluronic
One of F68, Tween 80, sorbester p17, fatty glyceride, polyalcohol sucrose ester, polyoxyethylene are a variety of.It is preferred that
Pluronic F68, fatty glyceride.
Further, of the present invention containing fluorocarbon emulsion type organ preservative fluid, the optional enuatrol of stabilizer, EDTA,
Lactobionic acid (lactone) it is one or more.It is preferred that enuatrol.
Further, of the present invention containing fluorocarbon emulsion type organ preservative fluid, the ingredient of electrolyte solution system can
Select sodium chloride, potassium chloride, magnesium chloride hexahydrate, calcium chloride dihydrate, epsom salt it is one or more.
Further, of the present invention containing fluorocarbon emulsion type organ preservative fluid, adjust the buffer salt solution body of pH value
The buffer system or hydrogen-oxygen of the optional histidine of the ingredient of system, tryptophan, one salt histidine of a water and 2-oxoglutaric acid hydrogen potassium composition
Change sodium, potassium hydroxide, potassium dihydrogen phosphate, potassium hydrogen phosphate and hydrochloric acid and forms buffer system.
Further, of the present invention containing fluorocarbon emulsion type organ preservative fluid, it is of the present invention to contain fluorocarbon emulsion
Type organ preservative fluid, emulsion partial size are that the fluorocarbon emulsion oxygen carrying content prepared and stability are suitable for device in 20-300 nanometer range
The particle size range of official's preservation condition.
This is further of the present invention to contain fluorocarbon emulsion type organ preservative fluid, the infiltration of the solution for organ preservation
Pressure (crystal/colloid) range is in 280-400mOsm/kgH thoroughly2O (280-400mmol/L), pH range are in 6.7-7.5；Sodium from
Sub- concentration 100-155mmol/L, potassium concentration 3.5-125mmol/L, 100-230/S at 37 DEG C of viscosity, above-mentioned parameter all connect
It is bordering on the relevant parameter of human plasma.
The present invention also provides the above-mentioned preparation methods containing fluorocarbon emulsion type organ preservative fluid：
Step 1：The oil-phase component for being insoluble in water is sufficiently mixed dissolution with blender by the preparation of oily phase.
Step 2：The preparation of water phase, by electrolyte solution system soluble easily in water, the buffer salt solution system of adjusting pH value
Ingredient carries out dissolution with water and mixes
Step 3：Colostrum is prepared, first by oily phase fluorocarbons and surfactant, emulsifier, adds water and mutually first stirs
Device or by forming stable O/W type colostrum in homogenizer or liquid at high speed cutter.
Step 4：Emulsion is prepared, surfactant is added in water phase, colostrum is added slowly in liquid at high speed cutter,
Colostrum is mixed with electrolyte solution part by homogenizer, dilutes, O/W type emulsion is made, while oxygen radical is added
Protective agent, stabilizer, the thickener for adjusting viscosity, mix well, finally homogenize 1-3 times repeatedly in high pressure homogenizer, prepare
Emulsion out adjusts pH value in 6.7-7.5, sterilizing both obtains product by partial size screening and filtering.
The present invention has prominent substantive distinguishing features and marked improvement compared with prior art：
The present invention develops new organ transplant and saves liquid, and the cold and oxygen deficient during organ transplant not only can be effectively reduced
Damage, while improving the rough sledding such as hyperkalemia hyponatremia, high viscosity, transplant organ can be improved in the intracorporal survival rate of host, from
And the transplanting including important organs such as lung, kidney, liver, hearts can be effectively applied to.
Main feature of the invention is to provide one kind containing fluorocarbon emulsion type organ preservative fluid, this preservation liquid can be donor
Organ interior tissue provides sufficient oxygen, solves to cause cell to damage because of existing organ preservative fluid anoxia-induced apoptosis when organ saves
The problem of hurting.
Feature of the invention includes providing a kind of emulsion-type organ preservative fluid that viscosity is low, this preservation fluid viscosity is low, is solved
The problem of UW fluid viscosity height is unfavorable for organ perfusion, this preservation liquid can be suitable for static organ simultaneously and save and organ perfusion's preservation
Two ways will not influence the perfusion effect of organ.
Feature of the invention further includes providing a kind of organ preservation solutions for adapting to large temperature range, this preservation liquid can fit
Should refrigerate with the state of temperatures such as room temperature, and be able to maintain the stability of emulsion, under 4 DEG C-room temperature the shelf-life up to 1 year or more,
Applicable temperature range is wider compared with other fluorocarbon emulsions.
Organ preservative fluid of the invention can not only save liver, can also save kidney, and heart and lung etc. need to move
The organ of plant.
Organ preservative fluid of the invention can be also used for being filled into the organ blood vessel of animal or human body, have good
Biocompatibility can improve the microcirculation of organ, improve the quality that organ saves.
Organ preservative fluid of the invention, osmotic pressure and human plasma are close, about 300-315mOsm/kgH2O, are cell
Normal physiological condition is kept to provide good simulated body fluid environment.
Detailed description of the invention
Fig. 1 is fluorocarbon emulsion type organ preservative fluid of the present invention compared with HTK liquid is to liver organ effect is saved (ALT)
Fig. 2 is fluorocarbon emulsion type organ preservative fluid of the present invention compared with HTK liquid is to liver organ effect is saved (AST)
Fig. 3 is fluorocarbon emulsion type organ preservative fluid of the present invention compared with HTK liquid is to kidney organ's effect is saved (MDA)
Specific embodiment
Embodiment 1
Organ preservative fluid of the invention can be achieved through the following technical solutions:A kind of organ preservative fluid, formula composition
It is as follows with concentration range (g/1000ml)：
Formula 1
Emulsion preparation process：It dissolves, is added on ultrasonator after first perfluorobromine is mixed with perfluoro bromide octane
10 grams of F68 with 10 grams of lecithin, 100 milliliters of pure water are added slowly and are sufficiently stirred under magnetic stirring apparatus, colostrum is formed.It will
Sodium chloride, potassium chloride, 2-oxoglutaric acid hydrogen potassium, magnesium chloride hexahydrate, one histidine monohydrochloride of a water, histidine, tryptophan, two water chlorine
Change calcium to be dissolved in 800 milliliters of water, is prepared into the water phase of electrolyte portion.In water phase be added 20 grams of F68, mannitol and
Colostrum is added in liquid at high speed cutter in stabilizer enuatrol slowly, and 3000-10000 revs/min of speed homogenizes 10 points
Clock repeats 2-3 times, finally in high pressure homogenizer, at 800-1000kg homogenizing under pressure 1-2 times, collects emulsion, measures emulsion
Partial size dilutes emulsion to 1000 milliliters, with hydrochloric acid adjustment pH value between 6.7-7.5, is sieved in 180-200 nanometer range, and 120
DEG C steam sterilizing, potting, both.Embodiment 2
Embodiment 2
The present invention provides a kind of organ preservative fluid, formula composition and concentration range (g/1000ml) are as follows：
Formula 2
Emulsion preparation process：It dissolves, is added on ultrasonator after first perfluoro bromide octane is mixed with perfluorobromine
10 grams of F68 with 10 grams of medium chain triglycerides, 100 milliliters of pure water are added slowly and are sufficiently stirred under magnetic stirring apparatus, are formed
Colostrum.By N-acetylcystein, adenosine, glutathione, Allopurinol, sodium hydroxide, potassium hydroxide, potassium dihydrogen phosphate, seven water
Magnesium sulfate is dissolved in 800 milliliters of water, is prepared into the water phase of electrolyte portion, adjusts PH in 6.8-7.5 range with hydrochloric acid.In water
20 grams of F68 are added in phase, hydroxy ethyl starch, lactobionic acid (lactone) add stabilizer enuatrol, after completely dissolution, in liquid
In body high-speed shearing machine, colostrum is added slowly, 3000-10000 revs/min of speed homogenizes 10 minutes, repetition 2-3 times, finally
In high pressure homogenizer, at 800-1000kg homogenizing under pressure 1-2 times, emulsion is collected, measures emulsion partial size at 180-200 nanometers
Range dilutes emulsion to 1000 milliliters, with hydrochloric acid adjustment pH value between 6.7-7.5, is sieved, 120 DEG C of steam sterilizings, potting,
Both.
Embodiment 3
The present invention provides a kind of organ preservative fluid, formula composition and concentration range (g/1000ml) are as follows：
Formula 3
Emulsion preparation process：It is dissolved on ultrasonator after first perfluoro-methyl Perhexiline is mixed with perfluorodecalin,
10 grams of F68 and 10 grams of egg yolk lecithin are added, 100 milliliters of pure water are added slowly and are sufficiently stirred under magnetic stirring apparatus, shape
At colostrum.By glutathione, Allopurinol, sodium chloride, potassium chloride, magnesium chloride hexahydrate, calcium chloride dihydrate, it is dissolved in 200 milliliters of water
In, it is configured to electrolyte solution；Again by histidine, tryptophan, one salt histidine of a water and 2-oxoglutaric acid hydrogen potassium with 500 milli
Electrolyte solution is added in buffer slowly and is merged into water phase by liter of water, with hydrochloric acid adjustment pH value in 6.7-7.5.In water
20 grams of F68 are added in phase, colostrum, 3000- is added in liquid at high speed cutter in mannitol and stabilizer enuatrol slowly
10000 revs/min of speed homogenizes 10 minutes, repeats 2-3 times, finally in high pressure homogenizer, under 800-1000kg pressure
It homogenizes 1-2 times, collects emulsion, dilute emulsion to 1000 milliliters, with hydrochloric acid adjustment pH value between 6.7-7.5, be sieved, 120 DEG C
High pressure sterilization, potting, both.
Embodiment 4
The present invention provides a kind of organ preservative fluids containing fluorocarbon emulsion, carry out oxygen concentration comparision contents with commercially available HTK liquid.
The nozzle for connecting oxygen tank is goed deep into this organ preservative fluid and HTK liquid level respectively, guarantees that bubble is successive, relatively steady
Determine to inflate at temperature at least 15 minutes.The oxygen content of each sample is detected with InPro 6860i Luminescence based Oxygen Sensor.Measurement before first with
Sodium hydrogensulfite saturated solution zeroising, with the saturated dissolved oxygen pure water tune 100% of fresh configuration.When instrumental correction by probe
It must be stirred into the water and simultaneously.It needs to write down water temperature with thermometer at this time.With the InPro of Mettler Toledo Inc.
6860i Luminescence based Oxygen Sensor measures.As a result the oxygen carrying content for prompting the organ preservative fluid of the invention containing fluorocarbon emulsion is HTK liquid
2 times or more, measurement result is as follows：
Table 1：
Embodiment 5
A kind of organ preservative fluid containing fluorocarbon emulsion studies the preservation effect of liver
The present invention provides a kind of organ preservative fluids, as shown in Figs. 1-2：It can save liver with the long period, improve and protect
Deposit liver mass.The hot ischemic of rat liver is after twenty minutes with HTK liquid lavation, then respectively in HTK and organ preservative fluid of the present invention
In 4 DEG C of preservation 48h and 72h, centre do not change liquid.Detect ALT in perfusate, AST content respectively after preservation.Organ saves
After 72h and 48h, ALT and AST level significantly increases in HTK preservation group perfusate, but fluorocarbon emulsion preservation group ALT and AST water
Put down still lower in 48h, also there is fluorocarbon emulsion preservation group ALT and AST level when to 72h increases, but is still below control HTK and protects
A group numerical value is deposited, the good hold capacity of fluorocarbon emulsion is prompted.
Embodiment 6
A kind of organ preservative fluid containing fluorocarbon emulsion is to kidney being kept in existence effect disquisition
The present invention provides a kind of organ preservative fluids, as shown in Figure 3：It can be improved with long period storage in vitro kidney
Save kidney quality.Then the hot ischemic of rat kidney is saved in HTK and organ of the present invention respectively after twenty minutes with HTK liquid lavation
4 DEG C of preservation 48h in liquid, centre do not change liquid.Detect MDA content in perfusate respectively after preservation.After kidney being kept in existence 48h,
MDA level significantly increases in HTK preservation group perfusate, but fluorocarbon emulsion preservation group MDA level is still lower, prompts fluorocarbon emulsion pair
Kidney has better hold capacity.
Claims (10)
1. one kind contains fluorocarbon emulsion type organ preservative fluid, which is characterized in that including Oxygen carrying agent, cell oxygen radical protective agent；
It further include emulsifier, surfactant, stabilizer, the thickener for adjusting viscosity, electrolyte solution system and adjusting pH value
Buffer salt solution system.
2. described in claim 1 contain fluorocarbon emulsion type organ preservative fluid, which is characterized in that Oxygen carrying agent w/v percentage
Content 5-50% (m/V), oxygen radical protective agent 0.001%-5%, emulsifier 0.001-15%, surfactant 0.001-
10%, stabilizer 0.001-5%, thickener 0.001-5%, remaining is water.
3. as claimed in claim 2 contain fluorocarbon emulsion type organ preservative fluid, which is characterized in that Oxygen carrying agent w/v percentage
Content 10-20% (m/V), oxygen radical protective agent 0.1%-2%, emulsifier 1-10%, surfactant 0.1-5% stablize
Agent 0.01-1%, thickener 0.001-2%, remaining is water.
4. containing fluorocarbon emulsion type organ preservative fluid described in claim 1-3 is any, which is characterized in that the Oxygen carrying agent uses
Fluorocarbons is selected from perfluoro bromide octane, perfluorobromine, perfluorodecalin, perfluamine, perfluoro-methyl Perhexiline, perfluor
One of tri-butylamine, perfluorodichlorooctane, perfluorobutyl ethylene are a variety of；The cell oxygen radical protective agent is selected from N-
One of acetylcysteine, vitamin E, Allopurinol, adenosine, glutathione are a variety of；The emulsifier is selected from soybean ovum
Phosphatide, egg yolk lecithin, median chain triglyceride oil, phosphatide, cholesterol acid ester, cholesterol, olein, poloxamer
One of 338 or a variety of；The surfactant be selected from Pluronic F68, Tween 80, sorbester p17, fatty glyceride,
One of polyalcohol sucrose ester, polyoxyethylene are a variety of；The thickener agent is selected from mannitol, hydroxy ethyl starch, cottonseed
One of sugar, lactobionic acid are a variety of；The stabilizer is selected from enuatrol, one of EDTA, lactobionic acid or a variety of.
5. as claimed in claim 4 contain fluorocarbon emulsion type organ preservative fluid, which is characterized in that the fluorocarbons is selected from complete
Fluorine bromooctane, perfluorobromine；The emulsifier is selected from egg yolk lecithin, median chain triglyceride oil；Surfactant is stated to be selected from
Pluronic F68, fatty glyceride；The thickener agent is selected from hydroxy ethyl starch, mannitol；The thickener is selected from
Hydroxy ethyl starch；The stabilizer is selected from enuatrol.
6. containing fluorocarbon emulsion type organ preservative fluid described in claim 1-5 is any, which is characterized in that electrolyte solution system
The optional sodium chloride of ingredient, potassium chloride, magnesium chloride hexahydrate, calcium chloride dihydrate, epsom salt it is one or more.
7. containing fluorocarbon emulsion type organ preservative fluid described in claim 1-5 is any, which is characterized in that the adjusting pH value
The optional histidine of the ingredient of buffer salt solution system, tryptophan, one salt histidine of a water and 2-oxoglutaric acid hydrogen potassium form slow
Rush system or sodium hydroxide, potassium hydroxide, potassium dihydrogen phosphate and hydrochloric acid composition buffer system.
8. containing fluorocarbon emulsion type organ preservative fluid described in claim 1-5 is any, which is characterized in that described to contain fluorine carbon cream
Dosage form organ preservative fluid, emulsion partial size are that the fluorocarbon emulsion oxygen carrying content prepared and stability are suitable in 20-300 nanometer range
The particle size range of organ preservation condition.
9. containing fluorocarbon emulsion type organ preservative fluid described in claim 1-5 is any, which is characterized in that saved for organ
Osmotic pressure (crystal/colloid) range of solution is in 280-400mOsm/kgH2O (280-400mmol/L), pH range are in 6.7-
7.5；Na ion concentration 100-155mmol/L, potassium concentration 3.5-125mmol/L, 100-230/S at 37 DEG C of viscosity are above-mentioned
Parameter is all close to the relevant parameter of human plasma.
10. any preparation method containing fluorocarbon emulsion type organ preservative fluid of claim 1-5, which is characterized in that packet
Include following steps：
Step 1：The oil-phase component for being insoluble in water is sufficiently mixed dissolution with blender by the preparation of oily phase.
Step 2：The preparation of water phase, by the buffer salt solution system ingredient of electrolyte solution system soluble easily in water, adjusting pH value
Dissolution is carried out with water to mix
Step 3：Prepare colostrum, first by oily phase fluorocarbons and surfactant, emulsifier, add water mutually first blender or
Stable O/W type colostrum is formed by homogenizer, in proportion by surfactant, emulsifier and water supersonic oscillations, with
And emulsification is prepared into O/W type colostrum in liquid at high speed cutter.
Step 4：Emulsion is prepared, surfactant is added in water phase, colostrum is added slowly in liquid at high speed cutter, it will be first
Cream is mixed with electrolyte solution part by homogenizer, dilutes, O/W type emulsion is made, while oxygen radical protection is added
Agent, stabilizer, the thickener for adjusting viscosity, mix well, finally homogenize 1-3 times repeatedly in high pressure homogenizer, prepare cream
Agent adjusts pH value in 6.7-7.5, sterilizing both obtains product by partial size screening and filtering.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811155379.8A CN108849861A (en) | 2018-09-30 | 2018-09-30 | One kind containing fluorocarbon emulsion type organ preservative fluid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811155379.8A CN108849861A (en) | 2018-09-30 | 2018-09-30 | One kind containing fluorocarbon emulsion type organ preservative fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108849861A true CN108849861A (en) | 2018-11-23 |
Family
ID=64325051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811155379.8A Pending CN108849861A (en) | 2018-09-30 | 2018-09-30 | One kind containing fluorocarbon emulsion type organ preservative fluid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108849861A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109769799A (en) * | 2019-03-20 | 2019-05-21 | 江苏瑞思坦生物科技有限公司 | A kind of human fat tissue saves liquid and preparation method thereof |
| CN113498777A (en) * | 2021-07-26 | 2021-10-15 | 公卫复医(上海)生物科技有限公司 | Emulsion type organ preservation solution and preparation method thereof |
| CN113767895A (en) * | 2021-09-23 | 2021-12-10 | 北京大麦植发技术研究有限公司 | Composite hair follicle tissue preservation solution, preparation method thereof and preservation method for maintaining hair follicle in-vitro activity |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1038022A (en) * | 1988-04-29 | 1989-12-20 | 赫门恩Pec公司 | The improvement Emulsion of highly fluorinated organic compounds |
| CN101014326A (en) * | 2004-03-01 | 2007-08-08 | 叶夫根尼·帕夫洛维奇·格尔马诺夫 | Medical emulsion of perfluororganic compounds and method for the production thereof |
| CN101019529A (en) * | 2007-03-22 | 2007-08-22 | 南京中脉生物医药有限公司 | Organ preserving fluid and its prepn |
| CN101491238A (en) * | 2009-03-06 | 2009-07-29 | 李立 | Organ preservation liquid |
| CN101496512A (en) * | 2008-02-01 | 2009-08-05 | 扬子江药业集团上海海尼药业有限公司 | Organ preservative fluid and preparation method thereof |
| CN101991595A (en) * | 2009-08-26 | 2011-03-30 | 温州医学院 | Plasma substitute and preparation method thereof |
| CN102000031A (en) * | 2010-11-17 | 2011-04-06 | 上海纳米技术及应用国家工程研究中心有限公司 | Method for preparing fluorocarbon microspheres |
| CN102395548A (en) * | 2009-04-15 | 2012-03-28 | 奥斯金生医公司 | Emulsions of perfluorocarbons |
-
2018
- 2018-09-30 CN CN201811155379.8A patent/CN108849861A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1038022A (en) * | 1988-04-29 | 1989-12-20 | 赫门恩Pec公司 | The improvement Emulsion of highly fluorinated organic compounds |
| CN101014326A (en) * | 2004-03-01 | 2007-08-08 | 叶夫根尼·帕夫洛维奇·格尔马诺夫 | Medical emulsion of perfluororganic compounds and method for the production thereof |
| CN101019529A (en) * | 2007-03-22 | 2007-08-22 | 南京中脉生物医药有限公司 | Organ preserving fluid and its prepn |
| CN101496512A (en) * | 2008-02-01 | 2009-08-05 | 扬子江药业集团上海海尼药业有限公司 | Organ preservative fluid and preparation method thereof |
| CN101491238A (en) * | 2009-03-06 | 2009-07-29 | 李立 | Organ preservation liquid |
| CN102395548A (en) * | 2009-04-15 | 2012-03-28 | 奥斯金生医公司 | Emulsions of perfluorocarbons |
| CN101991595A (en) * | 2009-08-26 | 2011-03-30 | 温州医学院 | Plasma substitute and preparation method thereof |
| CN102000031A (en) * | 2010-11-17 | 2011-04-06 | 上海纳米技术及应用国家工程研究中心有限公司 | Method for preparing fluorocarbon microspheres |
Non-Patent Citations (2)
| Title |
|---|
| 彭雪梅 等: "乳化氟碳保存液对离体保存肾脏抗氧化能力及组织结构的影响", 《暨南大学学报(医学版)》 * |
| 项捷 等: "全氟碳化合物在离体心脏长时程低温保存中的作用", 《上海交通大学学报(医学版)》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109769799A (en) * | 2019-03-20 | 2019-05-21 | 江苏瑞思坦生物科技有限公司 | A kind of human fat tissue saves liquid and preparation method thereof |
| CN113498777A (en) * | 2021-07-26 | 2021-10-15 | 公卫复医(上海)生物科技有限公司 | Emulsion type organ preservation solution and preparation method thereof |
| CN113767895A (en) * | 2021-09-23 | 2021-12-10 | 北京大麦植发技术研究有限公司 | Composite hair follicle tissue preservation solution, preparation method thereof and preservation method for maintaining hair follicle in-vitro activity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2112952A1 (en) | Methods, apparatus and perfusion-solutions for preservation of explanted organs | |
| Banan et al. | Development of a normothermic extracorporeal liver perfusion system toward improving viability and function of human extended criteria donor livers | |
| RU2019965C1 (en) | Composition for preservation and storage of organ to be implanted in patient | |
| US7575856B2 (en) | Compositions and methods for the evaluation and resuscitation of cadaveric hearts for transplant | |
| CN108849861A (en) | One kind containing fluorocarbon emulsion type organ preservative fluid | |
| CA2678486C (en) | Compositions and method for tissue preservation | |
| US4965185A (en) | Method for low-temperature preservation of embryos | |
| RU2396748C2 (en) | Medium for storage of cells | |
| EP0033402A1 (en) | Perfusate for preserving organ to be transplanted and preserving method | |
| JP2014040491A (en) | Compositions, methods and devices for maintaining organ | |
| Roberts et al. | A COMPARISON OF THE NEW PRESERVATION SOLUTION CELSIOR TO EURO-COLLINS AND UNIVERSITY OF WISCONSIN SOLUTIONS IN LUNG REPERFUSION INJURY1 | |
| Schröder et al. | Preclinical evaluation of coronary vascular function after cardioplegia with HTK and different antioxidant additives | |
| Bessems et al. | Machine perfusion preservation of the non–heart-beating donor rat livers using polysol, a new preservation solution | |
| CN115777696B (en) | Vitrification freezing thawing liquid suit | |
| CN105263321A (en) | Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation | |
| US20160088832A1 (en) | Formulations containing poly (0-2 hydroxyethyl) starch for increasing the oxygen-content, stability and shelf life of an organ and tissue preservation solution | |
| US20220071196A1 (en) | System and method for cryopreservation of tissues | |
| Toledo-Pereyra et al. | Kidney preservation | |
| Breuer et al. | Ion movements in seminal vesicle mucosa | |
| CA2032032A1 (en) | Internal organ-preserving liquid and method for preserving internal organs | |
| Sundberg et al. | Effects of chlorpromazine and methylprednisolone on perfusion preservation of rabbit livers | |
| Linask et al. | Perfusion preservation of hearts for 6 to 9 days at room temperature | |
| JP2949843B2 (en) | Organ preservation solution and organ preservation method | |
| WO2008070412A2 (en) | Methods and compositions for reanimating cryopreserved oocytes | |
| US5262442A (en) | Process for rapid thawing and storage of frozen fluorocarbon emulsion, and resultant product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181123 |
|
| WD01 | Invention patent application deemed withdrawn after publication |